VCYT Veracyte Inc

Price (delayed)

$46.81

Market cap

$3.16B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.01

Enterprise value

$2.85B

Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other ...

Highlights
Veracyte's gross profit has increased by 44% YoY and by 30% QoQ
Veracyte's revenue has increased by 40% YoY and by 28% QoQ
Veracyte's net income has shrunk by 104% YoY but it has increased by 3.1% QoQ
The EPS has dropped by 58% year-on-year but it has increased by 8% since the previous quarter
The company's quick ratio fell by 20% YoY and by 7% QoQ

Key stats

What are the main financial stats of VCYT
Market
Shares outstanding
67.47M
Market cap
$3.16B
Enterprise value
$2.85B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.24
Price to sales (P/S)
20.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.08
Earnings
Revenue
$157.47M
EBIT
-$66.8M
EBITDA
-$54.35M
Free cash flow
-$38.91M
Per share
EPS
-$1.01
Free cash flow per share
-$0.58
Book value per share
$14.44
Revenue per share
$2.34
TBVPS
$5.94
Balance sheet
Total assets
$1.03B
Total liabilities
$56.26M
Debt
$17.19M
Equity
$971.18M
Working capital
$335.24M
Liquidity
Debt to equity
0.02
Current ratio
10.29
Quick ratio
9.98
Net debt/EBITDA
5.72
Margins
EBITDA margin
-34.5%
Gross margin
67.3%
Net margin
-40.1%
Operating margin
-41.3%
Efficiency
Return on assets
-8.5%
Return on equity
-9%
Return on invested capital
-142.7%
Return on capital employed
-6.7%
Return on sales
-42.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VCYT stock price

How has the Veracyte stock price performed over time
Intraday
0.19%
1 week
-5.19%
1 month
20.74%
1 year
42.54%
YTD
-4.35%
QTD
17.08%

Financial performance

How have Veracyte's revenue and profit performed over time
Revenue
$157.47M
Gross profit
$106.03M
Operating income
-$65.03M
Net income
-$63.07M
Gross margin
67.3%
Net margin
-40.1%
Veracyte's net income has shrunk by 104% YoY but it has increased by 3.1% QoQ
The operating income has plunged by 96% YoY but it has grown by 5% from the previous quarter
The net margin has contracted by 46% YoY but it has grown by 24% from the previous quarter
Veracyte's gross profit has increased by 44% YoY and by 30% QoQ

Growth

What is Veracyte's growth rate over time

Valuation

What is Veracyte stock price valuation
P/E
N/A
P/B
3.24
P/S
20.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.08
The EPS has dropped by 58% year-on-year but it has increased by 8% since the previous quarter
The P/B is 47% below the 5-year quarterly average of 6.1 and 25% below the last 4 quarters average of 4.3
The P/S is 115% above the 5-year quarterly average of 9.3 but 3.3% below the last 4 quarters average of 20.7
Veracyte's revenue has increased by 40% YoY and by 28% QoQ

Efficiency

How efficient is Veracyte business performance
VCYT's return on invested capital has dropped by 106% year-on-year but it is up by 8% since the previous quarter
The return on sales has dropped by 55% year-on-year but it has increased by 24% since the previous quarter
The company's return on equity rose by 32% YoY and by 29% QoQ
The ROA has grown by 29% from the previous quarter and by 27% YoY

Dividends

What is VCYT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VCYT.

Financial health

How did Veracyte financials performed over time
The total liabilities has soared by 84% YoY and by 11% from the previous quarter
The company's current ratio fell by 22% YoY and by 7% QoQ
The debt is 98% less than the equity
VCYT's debt to equity has dropped by 67% year-on-year
The debt has grown by 32% YoY but it has contracted by 3.3% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.